RBX2660 (Rebyota, Ferring) is approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in adults who are at least 18 years of age, and is intended for use after a patient has completed antibiotic treatment for CDI recurrence.
“This is a major milestone in the translation of gut microbiome science to clinical solutions for patients. This accomplishment is based on decades of work on the gut microbiome by gastroenterologists and collaborators,” noted